[A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].

Ye, L; Ren, Y L; Xie, L L; Luo, Y W; Lin, P P; Zhou, X P; Ma, L Y; Mei, C; Xu, W L; Wei, J Y; Jiang, H F; Zhang, L M; Zeng, H; Tong, H Y

Ye, L; Ren, Y L; Xie, L L; Luo, Y W; Lin, P P; Zhou, X P; Ma, L Y; Mei, C; Xu, W L; Wei, J Y; Jiang, H F; Zhang, L M; Zeng, H; Tong, H Y.

Afiliação

Ye L; MDS Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Institute of Hematology, Zhejiang University, and Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310009, China.
Tong HY; MDS Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Institute of Hematology, Zhejiang University, and Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310009, China.

Zhonghua Xue Ye Xue Za Zhi ; 38(4): 307-312, 2017 Apr 14.

Article em Zh | MEDLINE | ID: mdl-28468092

Assuntos

Mutação; Síndromes Mielodisplásicas; Antimetabólitos Antineoplásicos; Azacitidina/análogos & derivados; Decitabina; Intervalo Livre de Doença; Humanos; Prognóstico; Risco; Resultado do Tratamento

Palavras-chave

Decitabine; Hypomethylating; Lower-risk; Myelodysplastic syndromes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Mutação Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Ano de publicação: 2017 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google